Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Letters
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-1074 Online ISSN: 1792-1082
Journal Cover
August-2026 Volume 32 Issue 2

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
August-2026 Volume 32 Issue 2

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article Open Access

Methylation of the BMP6, BRCA1, ESR2, GSTP1 and TIMP3 genes in Mexican women with breast cancer and benign disease

  • Authors:
    • Samantha Rebeca de la Torre-Guzmán
    • Andrea Marlene García Muro
    • Brenda Pelayo-Chávez
    • Carolina Vázquez-Gastélum
    • Martha Patricia Gallegos-Arreola
    • Ernesto Soto-Reyes
    • Sergio Osvaldo Meza-Chavolla
    • Josefina Yoaly Sánchez-López
  • View Affiliations / Copyright

    Affiliations: Genetics Division, Western Biomedical Research Center, Mexican Social Security Institute, Guadalajara, Jalisco 44340, Mexico, Department of Natural Sciences, Autonomous Metropolitan University‑Cuajimalpa (UAM‑C), Mexico City 05348, Mexico, Breast Detection and Diagnosis Unit, Mexican Social Security Institute, Guadalajara, Jalisco 44300, Mexico
    Copyright: © de la Torre-Guzmán et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 4.0].
  • Article Number: 368
    |
    Published online on: June 24, 2026
       https://doi.org/10.3892/ol.2026.15723
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:


Abstract

Breast cancer (BC) is the main cause of cancer‑related mortality in women and is influenced by genetic, environmental and lifestyle factors. The inactivation of tumor suppressor genes, such as bone morphogenetic protein 6 (BMP6), breast cancer susceptibility gene 1 (BRCA1), estrogen receptor 2 (ESR2), glutathione S‑transferase π1 (GSTP1) and tissue inhibitor of metalloproteinase 3 (TIMP3), via methylation may contribute to the development of BC. The present study analyzed the methylation status of these genes in 60 BC and benign disease (BD) tissue samples from Mexican women and the association with clinical and histopathological variables. DNA was modified with sodium bisulfite, followed by methylation‑specific PCR and electrophoresis, and analyzed using χ2 test, Fisher's exact test, logistic regression, odds ratio (OR) with 95% confidence interval and Kaplan‑Meier curves. The results indicated that the average age was higher in the BC group compared with that in the BD group (55 vs. 42 years; P<0.00001), with ≥50 years being a significant risk factor (OR, 5.44; P=0.00002). Only BRCA1 demonstrated a significant difference in methylation status, increasing the susceptibility to BC (OR, 2.50; P=0.0001), and tending to be associated with increased proliferation and lymph node metastasis. TIMP3 methylation was significantly associated with distant metastasis (OR, 8.65; P=0.028). Methylation of BRCA1 and TIMP3 demonstrated a significant association with poor prognosis in BC. BRCA1 was methylated more frequently in women with BC and TIMP3 was associated with a higher risk of distant metastasis. The present study highlighted the potential of these genes as prognostic biomarkers and the need to further explore DNA methylation for diagnostic and therapeutic purposes in future research.
View Figures

Figure 1

(A) Partial electropherogram of a DNA
sample positive for methylation in the BMP6 gene. The first
three arrows indicate three CG sites (methylated) detected by the
forward primer 5′-GGTTTAGAGTGATCGCGTC-3′ (bold) using MS-PCR (100%
concordance with DNA sequencing at these 3 sites) and the remaining
two arrows point to other (methylated) CG sites that were
visualized via DNA sequencing. The sequence described in NCBI
Reference Sequence: NC_000006.12 was used as a reference. (B)
Partial electropherogram of a DNA sample positive for methylation
in the BRCA1 gene. The arrow indicates a methylated CG site
not located within the primer sequence; in this case, as the primer
sequence is not visible, it is not possible to determine the
correspondence between the sites observed by MS-PCR and sequencing.
(C) Partial electropherogram of a DNA sample positive for
methylation in the ESR2 gene. The arrows indicate three CG
sites (methylated) not located within the primer sequence; in this
case, as the primer sequence is not presented, it is not possible
to determine the correspondence between the sites observed by
MS-PCR and sequencing. The sequence described in NCBI Reference
Sequence: NG_011535.1 was used as a reference. (D) Partial
electropherogram of a DNA sample positive for methylation in the
TIMP3 gene. The arrows indicate six CG sites (methylated);
the first three indicate sites not located in the primer sequence,
whilst the fourth, fifth and sixth arrows indicate other sites
located in the primer reverse 5′-GGCGCGTACGGTAATTTTGGAG-3′ (bold)
detected by MS-PCR (100% concordance at these 3 sites). MS-PCR,
methylation specific-PCR; BMP6, bone morphogenetic protein
6; BRCA1, breast cancer susceptibility gene 1; TIMP3,
tissue inhibitor of metalloproteinase 3; ESR2, estrogen
receptor 2; NCBI, National Center for Biotechnology
Information.

Figure 2

Kaplan-Meier curve according to
BMP6 promoter methylation. Median PFS was estimated from
time to progression and event status, that is, from the time of
diagnosis confirmed by histopathology up to 5 years of follow-up.
The probability of survival over the course of 12, 36 and 60 months
was evaluated using the log-rank test (Mantel-Cox). The blue line
represents patients with methylated BMP6 gene and the red
line represents unmethylated BMP6 gene. BMP6, bone
morphogenetic protein 6; PFS, progression-free survival.

Figure 3

Kaplan-Meier curve according to
BRCA1 promoter methylation. Median PFS was estimated from
time to progression and event status, that is, from the time of
diagnosis confirmed by histopathology up to 5 years of follow-up.
The probability of survival over the course of 12, 36 and 60 months
was evaluated using the log-rank test (Mantel-Cox). The blue line
represents patients with methylated BRCA1 gene and the red
line represents unmethylated BRCA1 gene. PFS,
progression-free survival; BRCA1, breast cancer
susceptibility gene 1.

Figure 4

Kaplan-Meier curve according to
ESR2 promoter methylation. Median PFS was estimated from
time to progression and event status, that is, from the time of
diagnosis confirmed by histopathology up to 5 years of follow-up.
The probability of survival over the course of 12, 36 and 60 months
was evaluated using the log-rank test (Mantel-Cox). The blue line
represents patients with methylated ESR2 gene and the red
line represents unmethylated ESR2 gene. ESR2,
estrogen receptor 2; PFS, progression-free survival.

Figure 5

Kaplan-Meier curve according to
GSTP1 promoter methylation. Median PFS was estimated from
time to progression and event status, that is, from the time of
diagnosis confirmed by histopathology up to 5 years of follow-up.
The probability of survival over the course of 12, 36 and 60 months
was evaluated using the log-rank test (Mantel-Cox). The blue line
represents patients with methylated GSTP1 gene and the red
line represents unmethylated GSTP1 gene. GSTP1,
glutathione S-transferase π1; PFS, progression-free survival.

Figure 6

Kaplan-Meier curve according to
TIMP3 promoter methylation. Median PFS was estimated from
time to progression and event status, that is, from the time of
diagnosis confirmed by histopathology up to 5 years of follow-up.
The probability of survival over the course of 12, 36 and 60 months
was evaluated using the log-rank test (Mantel-Cox). The blue line
represents patients with methylated TIMP3 gene and the red
line represents unmethylated TIMP3 gene. TIMP3,
tissue inhibitor of metalloproteinase 3; PFS, progression-free
survival.
View References

1 

World Health Organization (WHO), . Breast cancer. WHO; Geneva: 2025 October 28–2025https://www.who.int/news-room/fact-sheets/detail/breast-cancer

2 

American Cancer Society, . Breast Cancer. American Cancer Society; Hagerstown, MD: 2025 October 28–2025https://www.cancer.org/cancer/types/breast-cancer.html

3 

Provenzano E, Ulaner GA and Chin SF: Molecular classification of breast cancer. PET Clin. 13:325–338. 2018. View Article : Google Scholar : PubMed/NCBI

4 

Vietri MT, D'Elia G, Benincasa G, Ferraro G, Caliendo G, Nicoletti GF and Napoli C: DNA methylation and breast cancer: A way forward. Int J Oncol. 59:982021. View Article : Google Scholar : PubMed/NCBI

5 

Radpour R, Kohler C, Haghighi MM, Fan AX, Holzgreve W and Zhong XY: Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array. Oncogene. 28:2969–2978. 2009. View Article : Google Scholar : PubMed/NCBI

6 

Barekati Z, Radpour R, Lu Q, Bitzer J, Zheng H, Toniolo P, Lenner P and Zhong XY: Methylation signature of lymph node metastases in breast cancer patients. BMC Cancer. 12:2442012. View Article : Google Scholar : PubMed/NCBI

7 

Khan F, Agarwal P, Gupta S, Maurya MK, Singh P, Agarwal A, Singh K, Sonkar AA and Goel MM: BRCA1 promoter methylation and its immunohistochemical correlation in sporadic breast cancer. Indian J Med Res. 158:47–54. 2023. View Article : Google Scholar : PubMed/NCBI

8 

Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM and Haussler D: The human genome browser at UCSC. Genome Res. 12:996–1006. 2002. View Article : Google Scholar : PubMed/NCBI

9 

Radpour R, Barekati Z, Kohler C, Lv Q, Burki N, Diesch C, Bitzer J, Zheng H, Schmid S and Zhong XY: Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. PLoS One. 6:e160802011. View Article : Google Scholar : PubMed/NCBI

10 

Cui J, Li G, Yin J, Li L, Tan Y, Wei H, Liu B, Deng L, Tang J, Chen Y and Yi L: GSTP1 and cancer: Expression, methylation, polymorphisms and signaling (Review). Int J Oncol. 56:867–878. 2020.PubMed/NCBI

11 

Pongtheerat T, Pakdeethai S, Purisa W, Chariyalertsak S and Petmitr S: Promoter methylation and genetic polymorphism of glutathione S-transferase P1 gene (GSTP1) in Thai breast cancer patients. Asian Pac J Cancer Prev. 12:2731–2734. 2011.PubMed/NCBI

12 

Lui EL, Loo WT, Zhu L, Cheung MN and Chow LW: DNA hypermethylation of TIMP3 gene in invasive breast ductal carcinoma. Biomed Pharmacother. 59 (Suppl 2):S363–S365. 2005. View Article : Google Scholar : PubMed/NCBI

13 

Breastcancer.orgThe Breast Imaging Reporting and Data System (BI-RADS). Available from:. https://www.breastcancer.org/screening-testing/mammograms/bi-rads-resultsJune 19–2026

14 

Segovia-Alvarez G, Bonfil-Rodriguez MI, Valdivieso-Contreras L and Flores-Villegas J: Risk factors associated in breast cancer patients Mexico 2023. Br J Psychol Res. 11:59–70. 2023. View Article : Google Scholar

15 

National Cancer Institute (NCI), . Large study verifies cancer risk for women carrying BRCA1 or BRCA2 mutations. NCI; Maryland: 2025 October 28–2025https://www.cancer.gov/news-events/cancer-currents-blog/2017/brca-mutation-cancer-risk

16 

Blokzijl F, de Ligt J, Jager M, Sasselli V, Roerink S, Sasaki N, Huch M, Boymans S, Kuijk E, Prins P, et al: Tissue-specific mutation accumulation in human adult stem cells during life. Nature. 538:260–264. 2016. View Article : Google Scholar : PubMed/NCBI

17 

Shamah-Levy T, Lazcano-Ponce EC, Cuevas-Nasu L, Romero-Martínez M, Gaona-Pineda EB, Gómez-Acosta LM, Mendoza-Alvarado LR and Méndez-Gómez-Humarán I: Encuesta Nacional de Salud y Nutrición Continua 2023. Resultados Nacionales. Instituto Nacional de Salud Pública; Cuernavaca, México: 2024, https://insp.mx/resources/images/stories/2025/docs/250108_Ensanut_23.pdfJune 19–2026(In Spanish).

18 

Pati S, Irfan W, Jameel A, Ahmed S and Shahid RK: Obesity and cancer: A current overview of epidemiology, pathogenesis, outcomes, and management. Cancers (Basel). 15:4852023. View Article : Google Scholar : PubMed/NCBI

19 

Nguyen HL, Geukens T, Maetens M, Aparicio S, Bassez A, Borg A, Brock J, Broeks A, Caldas C, Cardoso F, et al: Obesity-associated changes in molecular biology of primary breast cancer. Nat Commun. 14:44182023. View Article : Google Scholar : PubMed/NCBI

20 

Lee K, Kruper L, Dieli-Conwright CM and Mortimer JE: The impact of obesity on breast cancer diagnosis and treatment. Curr Oncol Rep. 21:412019. View Article : Google Scholar : PubMed/NCBI

21 

Bhardwaj P, Au CM, Benito-Martin A, Ladumor H, Oshchepkova S, Moges R and Brown KA: Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression. J Steroid Biochem Mol Biol. 189:161–170. 2019. View Article : Google Scholar : PubMed/NCBI

22 

Rybinska I, Agresti R, Trapani A, Tagliabue E and Triulzi T: Adipocytes in breast cancer, the thick and the thin. Cells. 9:5602020. View Article : Google Scholar : PubMed/NCBI

23 

Aguilera-Eguia RA, Roco Videla A, Lopez-Soto OP, Herrera-Serna B and Fuentes-Barria H: Impact of adipose tissue on the development and progression of breast cancer: A crucial perspective. Nutrición Hospitalaria. 41:5182024.(In Spanish). PubMed/NCBI

24 

EPD, . The Eukaryotic Promoter Database. October 28–2025https://epd.expasy.org/epd/

25 

Deng G, Song GA, Pong E, Sleisenger M and Kim YS: Promoter methylation inhibits APC gene expression by causing changes in chromatin conformation and interfering with the binding of transcription factor CCAAT-binding factor. Cancer Res. 64:2692–2698. 2004. View Article : Google Scholar : PubMed/NCBI

26 

Vu TL, Nguyen TT, Doan VTH and Vo LTT: Methylation profiles of BRCA1, RASSF1A and GSTP1 in Vietnamese women with breast cancer. Asian Pac J Cancer Prev. 19:1887–1893. 2018.PubMed/NCBI

27 

Lobanova O, Medvedieva N, Fishchuk L, Dubitska O, Cheshuk V, Vereshchako R, Zakhartseva L, Rossokha Z and Gorovenko N: Methylation of promoter region of BRCA1 gene versus pathogenic variants of gene: Risk factor or clinical marker of breast cancer. Breast Cancer Res Treat. 196:505–515. 2022. View Article : Google Scholar : PubMed/NCBI

28 

Hassani H, Talaiezadeh A, Tahmasebi Birgani M and Bijanzadeh M: Evaluation of BRCA1 gene promoter methylation status in sporadic breast cancer patients in southwest of Iran. Asian Pac J Cancer Prev. 24:811–817. 2023. View Article : Google Scholar : PubMed/NCBI

29 

Jagtap SV and Jagtap SS: Methylation of BRCA1 promoter in sporadic breast cancer. Indian J Med Res. 158:85–87. 2023. View Article : Google Scholar : PubMed/NCBI

30 

Li Q, Wei W, Jiang YI, Yang H and Liu J: Promoter methylation and expression changes of BRCA1 in cancerous tissues of patients with sporadic breast cancer. Oncol Lett. 9:1807–1813. 2015. View Article : Google Scholar : PubMed/NCBI

31 

Hsu NC, Huang YF, Yokoyama KK, Chu PY, Chen FM and Hou MF: Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer. PLoS One. 8:e562562013. View Article : Google Scholar : PubMed/NCBI

32 

Oubaddou Y, Oukabli M, Fenniche S, Elktaibi A, Elochi MR, Al Bouzidi A, Qmichou Z, Dakka N, Diorio C, Richter A, et al: BRCA1 promoter hypermethylation in malignant breast tumors and in the histologically normal adjacent tissues to the tumors: Exploring its potential as a biomarker and its clinical significance in a translational approach. Genes (Basel). 14:16802023. View Article : Google Scholar : PubMed/NCBI

33 

Panagopoulou M, Panou T, Gkountakos A, Tarapatzi G, Karaglani M, Tsamardinos I and Chatzaki E: BRCA1 & BRCA2 methylation as a prognostic and predictive biomarker in cancer: Implementation in liquid biopsy in the era of precision medicine. Clin Epigenetics. 16:1782024. View Article : Google Scholar : PubMed/NCBI

34 

García AM: Evaluation of the methylation status of the BMP6 gene promoter in breast tissue and serum levels of BMP6 protein in Mexican women with breast cancer (unpublished PhD thesis) (In Spanish). Universidad de Guadalajara; 2023

35 

Liu J, Huang B, Ding F and Li Y: Environment factors, DNA methylation, and cancer. Environ Geochem Health. 45:7543–7568. 2023. View Article : Google Scholar : PubMed/NCBI

36 

Maleknia M, Ahmadirad N, Golab F, Katebi Y and Haj Mohamad Ebrahim Ketabforoush A: DNA methylation in cancer: Epigenetic view of dietary and lifestyle factors. Epigenet Insights. 16:251686572311998932023. View Article : Google Scholar : PubMed/NCBI

37 

Duthie SJ: Epigenetic modifications and human pathologies: Cancer and CVD. Proc Nutr Soc. 70:47–56. 2011. View Article : Google Scholar : PubMed/NCBI

38 

Kader F and Ghai M: DNA methylation-based variation between human populations. Mol Genet Genomics. 292:5–35. 2017. View Article : Google Scholar : PubMed/NCBI

39 

Domingo-Relloso A, Huan T, Haack K, Riffo-Campos AL, Levy D, Fallin MD, Terry MB, Zhang Y, Rhoades DA, Herreros-Martinez M, et al: DNA methylation and cancer incidence: lymphatic-hematopoietic versus solid cancers in the Strong Heart Study. Clin Epigenetics. 13:432021. View Article : Google Scholar : PubMed/NCBI

40 

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I and Bray F: Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer; Lyon: 2024, https://gco.iarc.who.int/media/globocan/factsheets/cancers/20-breast-fact-sheet.pdfMay 29–2026

41 

Elhanani O, Ben Uri R and Keren L: Spatial profiling technologies illuminate the tumor microenvironment. Cancer Cell. 41:404–420. 2023. View Article : Google Scholar : PubMed/NCBI

42 

Daraei A, Izadi P, Khorasani G, Nafissi N, Naghizadeh MM, Meysamie A, Mansoori Y, Nariman-Saleh-Fam Z, Bastami M, Saadatian Z, et al: A methylation signature at the CpG island promoter of estrogen receptor beta (ER-β) in breasts of women may be an early footmark of lack of breastfeeding and nulliparity. Pathol Res Pract. 218:1533282021. View Article : Google Scholar : PubMed/NCBI

43 

Zhu X, Leav I, Leung YK, Wu M, Liu Q, Gao Y, McNeal JE and Ho SM: Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol. 164:2003–2012. 2004. View Article : Google Scholar : PubMed/NCBI

44 

Arai T, Miyoshi Y, Kim SJ, Taguchi T, Tamaki Y and Noguchi S: Association of GSTP1 CpG islands hypermethylation with poor prognosis in human breast cancers. Breast Cancer Res Treat. 100:169–176. 2006. View Article : Google Scholar : PubMed/NCBI

45 

Song B, Wang L, Zhang Y, Li N, Dai H, Xu H, Cai H and Yan J: Combined detection of HER2, Ki67, and GSTP1 genes on the diagnosis and prognosis of breast cancer. Cancer Biother Radiopharm. 34:85–90. 2019.PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
de la Torre-Guzmán S, García Muro A, Pelayo-Chávez B, Vázquez-Gastélum C, Gallegos-Arreola M, Soto-Reyes E, Meza-Chavolla S and Sánchez-López J: Methylation of the <em>BMP6</em>, <em>BRCA1</em>, <em>ESR2</em>, <em>GSTP1</em> and <em>TIMP3</em> genes in Mexican women with breast cancer and benign disease. Oncol Lett 32: 368, 2026.
APA
de la Torre-Guzmán, S., García Muro, A., Pelayo-Chávez, B., Vázquez-Gastélum, C., Gallegos-Arreola, M., Soto-Reyes, E. ... Sánchez-López, J. (2026). Methylation of the <em>BMP6</em>, <em>BRCA1</em>, <em>ESR2</em>, <em>GSTP1</em> and <em>TIMP3</em> genes in Mexican women with breast cancer and benign disease. Oncology Letters, 32, 368. https://doi.org/10.3892/ol.2026.15723
MLA
de la Torre-Guzmán, S., García Muro, A., Pelayo-Chávez, B., Vázquez-Gastélum, C., Gallegos-Arreola, M., Soto-Reyes, E., Meza-Chavolla, S., Sánchez-López, J."Methylation of the <em>BMP6</em>, <em>BRCA1</em>, <em>ESR2</em>, <em>GSTP1</em> and <em>TIMP3</em> genes in Mexican women with breast cancer and benign disease". Oncology Letters 32.2 (2026): 368.
Chicago
de la Torre-Guzmán, S., García Muro, A., Pelayo-Chávez, B., Vázquez-Gastélum, C., Gallegos-Arreola, M., Soto-Reyes, E., Meza-Chavolla, S., Sánchez-López, J."Methylation of the <em>BMP6</em>, <em>BRCA1</em>, <em>ESR2</em>, <em>GSTP1</em> and <em>TIMP3</em> genes in Mexican women with breast cancer and benign disease". Oncology Letters 32, no. 2 (2026): 368. https://doi.org/10.3892/ol.2026.15723
Copy and paste a formatted citation
x
Spandidos Publications style
de la Torre-Guzmán S, García Muro A, Pelayo-Chávez B, Vázquez-Gastélum C, Gallegos-Arreola M, Soto-Reyes E, Meza-Chavolla S and Sánchez-López J: Methylation of the <em>BMP6</em>, <em>BRCA1</em>, <em>ESR2</em>, <em>GSTP1</em> and <em>TIMP3</em> genes in Mexican women with breast cancer and benign disease. Oncol Lett 32: 368, 2026.
APA
de la Torre-Guzmán, S., García Muro, A., Pelayo-Chávez, B., Vázquez-Gastélum, C., Gallegos-Arreola, M., Soto-Reyes, E. ... Sánchez-López, J. (2026). Methylation of the <em>BMP6</em>, <em>BRCA1</em>, <em>ESR2</em>, <em>GSTP1</em> and <em>TIMP3</em> genes in Mexican women with breast cancer and benign disease. Oncology Letters, 32, 368. https://doi.org/10.3892/ol.2026.15723
MLA
de la Torre-Guzmán, S., García Muro, A., Pelayo-Chávez, B., Vázquez-Gastélum, C., Gallegos-Arreola, M., Soto-Reyes, E., Meza-Chavolla, S., Sánchez-López, J."Methylation of the <em>BMP6</em>, <em>BRCA1</em>, <em>ESR2</em>, <em>GSTP1</em> and <em>TIMP3</em> genes in Mexican women with breast cancer and benign disease". Oncology Letters 32.2 (2026): 368.
Chicago
de la Torre-Guzmán, S., García Muro, A., Pelayo-Chávez, B., Vázquez-Gastélum, C., Gallegos-Arreola, M., Soto-Reyes, E., Meza-Chavolla, S., Sánchez-López, J."Methylation of the <em>BMP6</em>, <em>BRCA1</em>, <em>ESR2</em>, <em>GSTP1</em> and <em>TIMP3</em> genes in Mexican women with breast cancer and benign disease". Oncology Letters 32, no. 2 (2026): 368. https://doi.org/10.3892/ol.2026.15723
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team